Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient

Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient

Abstract The safety and efficacy of CAR T‐cell therapy are unknown in pediatric and adolescent patients with relapsed or refractory primary mediastinal large B‐cell lymphoma (R/R PMBCL) which is associated with dismal prognosis. Here, we present a case report of a 16‐year‐old patient with R/R PMBCL...

Full description

Bibliographic Details
Main Authors: Dasom Lee, Anmol Goyal, William L Wang, Snegha Ananth, Eric Lau, Michael S Binkley, Sushma Bharadwaj, Saurabh Dahiya
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:eJHaem
Subjects:
adolescent
AYA
lisocabtagene maraleucel
outcome
primary mediastinal large B‐cell lymphoma
refractory
Online Access:https://doi.org/10.1002/jha2.859

Internet

https://doi.org/10.1002/jha2.859

Similar Items